During the last session, Regenxbio Inc (NASDAQ:RGNX)’s traded shares were 0.52 million, with the beta value of the company hitting 1.22. At the end of the trading day, the stock’s price was $9.89, reflecting an intraday gain of 6.46% or $0.6. The 52-week high for the RGNX share is $28.80, that puts it down -191.2 from that peak though still a striking 7.89% gain since the share price plummeted to a 52-week low of $9.11. The company’s market capitalization is $488.76M, and the average intraday trading volume over the past 10 days was 0.56 million shares, and the average trade volume was 520.12K shares over the past three months.

Regenxbio Inc (RGNX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.30. RGNX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.12.

Regenxbio Inc (NASDAQ:RGNX) trade information

Regenxbio Inc (RGNX) registered a 6.46% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.46% in intraday trading to $9.89, hitting a weekly high. The stock’s 5-day price performance is 1.75%, and it has moved by -18.80% in 30 days. Based on these gigs, the overall price performance for the year is -41.17%. The short interest in Regenxbio Inc (NASDAQ:RGNX) is 5.31 million shares and it means that shorts have 9.58 day(s) to cover.

The consensus price target of analysts on Wall Street is $38, which implies an increase of 73.97% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $40 respectively. As a result, RGNX is trading at a discount of -304.45% off the target high and -82.0% off the low.

Regenxbio Inc (RGNX) estimates and forecasts

Statistics show that Regenxbio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Regenxbio Inc (RGNX) shares have gone down -45.33% during the last six months, with a year-to-date growth rate more than the industry average at 22.59% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 20.60% this quarter and then jump 20.30% in the quarter after that. In the rating firms’ projections, revenue will increase 7.10% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 23.42M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 24.17M by the end of current fiscal year.

While earnings are projected to return 24.63% in 2024, the next five years will return 13.60% per annum.

RGNX Dividends

Regenxbio Inc is due to release its next quarterly earnings on 2024-Nov-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Regenxbio Inc (NASDAQ:RGNX)’s Major holders

Regenxbio Inc insiders own 7.41% of total outstanding shares while institutional holders control 92.39%, with the float percentage being 99.78%. BLACKROCK INC. is the largest shareholder of the company, while 266.0 institutions own stock in it. As of 2024-06-30, the company held over 8.61 million shares (or 18.8252% of all shares), a total value of $100.73 million in shares.

The next largest institutional holding, with 5.11 million shares, is of VANGUARD GROUP INC’s that is approximately 11.1818% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $59.83 million.